Bosanquet A G
Bath Cancer Research Unit, Wolfson Centre, Royal United Hospital, UK.
Lancet. 1991 Mar 23;337(8743):711-4. doi: 10.1016/0140-6736(91)90287-y.
To develop the differential staining cytotoxicity (DiSC) assay, an in-vitro drug sensitivity test designed specifically for use with fresh human haematological tumour cells, into a predictive test for response to therapy as well as a tool for identifying new treatment strategies, test results have been correlated with response in patients with haematological malignancies. 22 of 119 tests indicated extreme drug resistance (tumour cell survival greater than 55%) in vitro. None of these patients responded to chemotherapy. The proportion of patients responding to therapy and 50% patient survival rose with in-vitro drug sensitivity. 11 specimens showing extreme drug resistance to the agents prescribed for the patient were subjected to drug sensitivity tests of drugs not prescribed; patients showing some sensitivity to these drugs had better survival than did those with extreme drug resistance to all drugs tested. The DiSC assay can also be used to identify new agents worth testing in clinical trials, and cross resistance profiles of new agents may indicate what combinations might be useful.
为了将差异染色细胞毒性（DiSC）检测法（一种专门用于新鲜人类血液肿瘤细胞的体外药物敏感性测试）发展成为一种治疗反应预测测试以及识别新治疗策略的工具，已将测试结果与血液系统恶性肿瘤患者的反应进行了关联。119项测试中有22项显示体外存在极端耐药性（肿瘤细胞存活率大于55%）。这些患者中无一例对化疗有反应。随着体外药物敏感性的提高，对治疗有反应的患者比例和50%的患者生存率有所上升。对为患者开具的药物表现出极端耐药性的11份标本进行了未开具药物的药物敏感性测试；对这些药物表现出一定敏感性的患者比那些对所有测试药物都有极端耐药性的患者生存情况更好。DiSC检测法还可用于识别值得在临床试验中测试的新药物，新药物的交叉耐药谱可能表明哪些联合用药可能有用。
